SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
August 7, 2003 (Date of earliest event reported)
Commission File Number 000-19627
BIOLASE TECHNOLOGY, INC.
(Exact Name of Registrant as Specified in Its Charter)
| Delaware | 000-19627 | 87-0442441 | ||
| (State or Other Jurisdiction of Incorporation or Organization) |
(Commission file number) |
(I.R.S. Employer Identification No.) |
981 Calle Amanecer
San Clemente, California 92673
(Address of Principal Executive Offices, Including Zip Code)
(949) 361-1200
(Registrant’s Telephone Number, Including Area Code)
Item 7. Financial Statements and Exhibits.
| (c) | Exhibits. |
| 99.1 | Press Release, dated August 7, 2003. |
Item 12. Results of Operations and Financial Condition.
On August 7, 2003, BioLase Technology, Inc. issued a press release announcing that it and its independent accountants have decided to seek guidance from the Securities and Exchange Commission regarding the accounting affect of certain language in the BioLase’s purchase order forms. A copy of the press release is attached herewith as Exhibit 99.1.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Dated: August 13, 2003 |
BIOLASE TECHNOLOGY, INC., (Registrant) | |||||||
| By: |
/s/ EDSON J. ROOD | |||||||
| Edson J. Rood Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) | ||||||||
3